Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling via IL-4Rα inhibition, has emerged as an effective treatment for CRSwNP and asthma, offering significant reductions in nasal polyp burden, improvements in quality of life, and better asthma control.3 The gene discussed is IL4R; the disease is asthma.